Think of the Neurokinin-1 Antagonists as Equally Efficacious

January 2016

Rolapitant (Varubi) will compete with older neurokinin-1 antagonists to prevent chemotherapy-induced nausea and vomiting.

It will join oral aprepitant and IV fosaprepitant (Emend, etc) and the combo of netupitant and the 5-HT3 antagonist palonosetron (Akynzeo).

We know that highly emetogenic chemotherapy (cisplatin, etc) requires using a three-drug regimen of a neurokinin-1 (NK-1) antagonist... 5-HT3 antagonist (ondansetron, etc)...and dexamethasone.

Get concise advice on drug therapy, plus unlimited access to CE

Hospital Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote